AURA vs SLS
AURA: Aura Biosciences is a clinical-stage biotech developing precision Viral-like Drug Conjugate (VDC) therapies designed to treat solid tumors while preserving organ function. SLS: SELLAS Life Sciences is a clinical-stage biotech developing targeted immunotherapies and small molecule inhibitors to treat a variety of hematologic and solid tumor cancers.
Side-by-side fundamentals
| Metric | AURA | SLS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.01 | $12.08 | |
| Market cap as of 2026-07-23 | $725M | $2.2B | |
| Net margin as of 2026-07-23 | n/a | -736.2% | |
| Gross margin as of 2026-07-23 | n/a | +93.1% | |
| Operating margin as of 2026-07-23 | n/a | -730.7% | |
| ROE as of 2026-07-23 | -78.1% | -47.1% | SLS higher |
| ROA as of 2026-07-23 | -64.1% | -42.6% | SLS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 0.40 | 2.49 | |
| 1-year return as of 2026-07-22 close | +3.8% | +556.5% | SLS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.